Colombia Wound Care Biologics Market Forecast to 2033

Technological Advancements in Biologic Wound Therapies to Drive Colombia Wound Care Biologics Market to USD 29.5 Mn by 2033 at 10.2% CAGR – Coherent Market Insights

Colombia Wound Care Biologics Market, by Product Type (Biologic Skin Substitutes, Enzyme Based Formulations, and Growth Factors), by Application (Chronic Wounds (Diabetic Foot Ulcer, Venous Leg Ulcer, and Pressure Ulcer) and Acute Wounds (Surgical Wounds and Burns)), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Home Care Settings), is estimated to be valued at USD 15 million in 2026 and is expected to exhibit a CAGR of 10.2% over the forecast period (2026-2033), as highlighted in a new report published by Coherent Market Insights.

Key players operating in the market are focusing on securing regulatory approvals and clearances for advanced biologic wound-care products, which is expected to support market growth over the forecast period.

For instance, in February 2026, Royal Wound-X, Inc. received U.S. FDA 510(k) clearance for its PRF-Matrix System, marketed as the Fibrinet PRF Wound Matrix. The point-of-care system prepares autologous platelet-rich plasma gel for managing cutaneous wounds, including diabetic ulcers, venous leg ulcers, and mechanically or surgically debrided wounds.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/colombia-wound-care-biologics-market-4892

Key players operating in the market are adopting inorganic growth strategies, including licensing, distributor partnerships, hospital-channel collaborations, and private-label agreements, to strengthen their commercialization capabilities in Colombia. For instance, in April 2026, Oneness Biotech announced a partnership-led market-access strategy for its Bonvadis wound-care product, with Colombia identified among its approved 2026 launch markets. The strategy includes collaboration with distributors, hospitals, licensing partners, and private-label companies. This followed INVIMA’s February 2026 authorization permitting Bonvadis to be marketed in Colombia for acute wounds, chronic wounds, diabetic foot ulcers, pressure ulcers, venous ulcers, burns, and post-surgical wounds.

Market Opportunity

The growing burden of diabetes and hard-to-heal wounds presents a significant opportunity for biologic skin substitutes, collagen matrices, growth-factor therapies, and regenerative wound-care products in Colombia. The International Diabetes Federation estimates that approximately 3.03 million Colombian adults were living with diabetes in 2024, including around 490,000 undiagnosed cases, while the affected population is projected to reach 4.28 million by 2050.

For instance, in February 2026, Oneness Biotech Co., Ltd. received INVIMA marketing authorization for Bonvadis topical wound dressing under registration number INVIMA2026DM-0032092. The authorization covers diabetic foot ulcers, pressure ulcers, venous ulcers, burns, acute wounds, and post-surgical wounds, with the company planning marketing and distribution activities in Colombia. This approval demonstrates an improving regulatory and commercialization pathway for advanced wound-care products and creates opportunities for biologics manufacturers to establish local distribution partnerships, secure hospital adoption, and introduce regenerative therapies for complex wounds. (Source: Oneness Biotech Co., Ltd.)

Market Trends

Innovation in fenestrated biologic skin substitutes: Product developers are focusing on allograft designs that improve fluid transfer, drainage, moisture management, conformability, and tissue integration. For instance, in July 2026, BioStem Technologies received four U.S. design patents covering fenestrated human placental allografts developed for surgical and wound care applications. (Source: BioStem Technologies)
Growing adoption of placental-derived wound care products: Healthcare providers are increasingly adopting placental and perinatal tissue allografts for managing chronic, acute, deep, and difficult-to-heal wounds. For instance, in January 2026, Tiger BioSciences launched a dedicated Dermatology Division providing access to placental-derived wound care tissue products, HealPack surgical dressings, clinical education, and specialized provider support. (Source: Tiger BioSciences)
Increasing demand for clinically validated biologic wound solutions: Hospitals and wound care centers are placing greater emphasis on randomized clinical evidence before adopting advanced biologic products. For instance, in April 2026, Organogenesis reported that a 170-patient randomized controlled trial of PuraPly AM achieved statistically significant diabetic foot ulcer closure at 12 weeks compared with standard care alone. (Source: Organogenesis)
Launch of thicker and easier-to-handle placental allografts: Manufacturers are developing biologic grafts with improved handling, positioning, suturing, and coverage of complex wounds. For instance, in March 2026, MIMEDX launched CHORIOFIX, a dual-layer chorion placental allograft intended to provide a protective environment for acute and chronic wounds, including deep and tunneling wounds. (Source: MIMEDX)

Key Takeaways of the Colombia Wound Care Biologics Market

The Colombia wound care biologics market is expected to exhibit a CAGR of 10.2% over the forecast period, supported by increasing product launches and the commercialization of advanced biologic wound care solutions. For instance, in January 2026, Tiger BioSciences launched a dedicated Dermatology Division to expand healthcare providers’ access to its advanced placental-derived wound care tissue products and HealPACK surgical dressings for acute and chronic wound management.
Key players operating in the Colombia wound care biologics market include Smith & Nephew, Plc, Organogenesis, Inc., Integra Life Sciences Corporation, MiMedx Group, Inc., Skye Biologics, Inc., Amino Technology LLC, Osiris Therapeutics, Inc., Alphatec Holdings, Inc. Mallinckrodt Plc., Amniox Medical, Inc., Acelity L.P. Inc., ConvaTec Group Plc, Generex Biotechnology Corporation, and Olaregen Therapeutix Inc.

Key Developments

In April 2026, AVITA Medical announced that it would showcase its acute burn and wound-care portfolio at the American Burn Association Annual Meeting. Across 19 presentations and three company-sponsored events, AVITA and its clinical partners highlighted RECELL, Cohealyx, and PermeaDerm. The program included interim findings from the multicenter Cohealyx-I study evaluating time to skin grafting, along with real-world evidence suggesting RECELL may reduce hospital stays and improve resource utilization. (Source: AVITA Medical)
In February 2026, Oneness Biotech announced that Bonvadis topical cream received INVIMA medical-device marketing authorization under registration number INVIMA2026DM-0032092. The approval permits commercialization in Colombia for acute and chronic wounds, including diabetic foot ulcers, pressure ulcers, venous ulcers, burns, and post-surgical wounds. The company plans to initiate local marketing and distribution activities, expanding access to advanced wound-management products.
In February 2026, Royal Biologics partnered with Jellagen to develop wound matrices, regenerative scaffolds, and implantable solutions using jellyfish-derived Collagen Type Zero. The non-mammalian material is designed to reduce disease-transmission and sourcing concerns associated with conventional bovine and porcine collagen while supporting tissue compatibility and regenerative healing. The innovation could influence future product development and market-entry strategies in Colombia.